Valuation : Alzinova AB

Market Cap 167M 17.43M 15M 14.11M 12.89M 24.12M 1.65B 24.18M 64.72M 844M 65.46M 64.03M 2.72B P/E 2026 *
-3.05x
P/E 2027 * -2.17x
Enterprise Value 151M 15.76M 13.56M 12.76M 11.66M 21.8M 1.49B 21.86M 58.51M 763M 59.18M 57.89M 2.46B EV / Sales 2026 *
4.81x
EV / Sales 2027 * -
Free-Float
75.07%
Yield 2026 *
-
Yield 2027 * -
1 day-3.18%
1 week-2.02%
Current month+2.88%
1 month-19.94%
3 months+84.53%
6 months+39.26%
Current year-0.72%
1 week 0.77
Extreme 0.77
0.86
1 month 0.75
Extreme 0.751
1.14
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.18%-2.02%-42.21%-73.75% 17.43M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -1.15%+0.28%+61.13%+89.26% 27.5B
Weighted average by Cap. -1.03%+0.11%+89.41%+127.92%

Financials

2026 *2027 *
Net sales 31.35M 3.28M 2.82M 2.65M 2.42M 4.53M 309M 4.55M 12.17M 159M 12.31M 12.04M 511M -
Net income -4.45M -465K -400K -377K -344K -644K -43.92M -645K -1.73M -22.53M -1.75M -1.71M -72.59M -77M -8.05M -6.93M -6.52M -5.95M -11.14M -760M -11.17M -29.88M -390M -30.22M -29.56M -1.26B
Net Debt -16M -1.67M -1.44M -1.35M -1.24M -2.31M -158M -2.32M -6.21M -81.02M -6.28M -6.14M -261M -19M -1.99M -1.71M -1.61M -1.47M -2.75M -188M -2.76M -7.37M -96.21M -7.46M -7.29M -310M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
04/09/26 SEK 0.8230 -3.18% 939,919
03/09/26 SEK 0.8500 -0.35% 666,382
02/09/26 SEK 0.8530 +5.57% 1,411,147
01/09/26 SEK 0.8080 +1.00% 707,328
31/08/26 SEK 0.8000 -4.76% 680,209

Annual profits - Rate of surprise